42 In Vitro Pharmacology CROs

What is in vitro pharmacology and when do you need it?

In vitro pharmacology is the bench work that proves your molecule does what you think it does, at the level of a purified protein or a living cell, before any animal is dosed. It answers the most basic questions a program has to clear: does the compound bind or modulate its intended target, how potent is it, is it selective, and does it trip any obvious off-target liability that would sink the program later. The work is done in a dish (in vitro, literally "in glass"), which is exactly why it is fast and cheap relative to everything downstream.

You reach for this work right after discovery hands you a lead or a short series. Discovery may have screened thousands of compounds; in vitro pharmacology is where you characterize the few survivors properly, with clean dose-response and orthogonal confirmation, so you can rank them and pick what to carry into in vivo efficacy and DMPK. It is also where you generate the target-engagement and selectivity data a later IND package leans on, and where cardiac and other safety flags first surface. Catching a hERG problem in a patch-clamp assay is a great deal cheaper than discovering it in a tox study.

Almost all of this is non-GLP, decision-grade science. Its purpose is to inform your go/no-go calls, not to satisfy a regulator, so it runs under good scientific practice with qualified assays and traceable data rather than full GLP. That distinction is what keeps the budget sane: you fail weak candidates here, on inexpensive assays, before you commit to the expensive studies that follow. The assay menu does shift by modality. A small molecule leans on enzyme and receptor assays and a hERG read; an antibody leans on binding affinity (SPR or BLI), cell-based functional potency, and FcgR or complement panels.

What does an in vitro pharmacology CRO actually do?

A good in vitro pharmacology CRO is, in practice, an assay shop with deep pharmacology judgment. They build or already run the readout that reports your compound's activity, qualify it so the numbers are reproducible, then generate the binding, potency, selectivity, and liability data you use to choose a candidate. The specific assays depend on your target class and modality, but the core menu is consistent across vendors.

• Target engagement and potency: biochemical (enzyme, kinase, GPCR) and cell-based assays with full dose-response, reporting IC50, EC50, Ki, or Kd so you can rank compounds on real potency, not single-point activity.
• Binding kinetics and affinity: SPR (Biacore), BLI (Octet), or radioligand binding to measure on/off rates and affinity, which matters most for biologics and for residence-time-driven programs.
• Functional assays: agonist, antagonist, or inverse-agonist characterization, second-messenger readouts (cAMP, calcium flux, beta-arrestin), and reporter-gene systems that show the compound's actual functional effect, not just that it binds.
• Selectivity and off-target screening: counter-screens against related family members (a kinase panel, a GPCR panel) and broad safety-pharmacology profiling (such as a CEREP-style panel) to catch promiscuity before it becomes a clinical surprise.
• Cardiac and ion-channel liability: hERG by manual or automated patch-clamp, plus other cardiac ion channels (Nav1.5, Cav1.2) and a CiPA-aligned panel where pro-arrhythmia risk is a real concern.
• Mechanism-of-action and cellular readouts: proliferation, viability, apoptosis, reporter assays, and target-engagement assays (CETSA, NanoBRET) that connect binding to a cellular consequence.

How do you choose an in vitro pharmacology CRO?

Start with fit to your target class and modality, not the size of the logo. A lab that runs flawless kinase enzyme assays may have never touched a GPCR functional panel or an antibody potency assay, and the right assay format for an ion channel is nothing like the right format for a nuclear receptor. The vendor whose existing, validated assay already detects your compound at the concentration you care about is worth more than a bigger shop spinning the assay up for the first time on your budget.

The other thing that separates a clean engagement from a frustrating one is how they report. You want the raw curves, the fit parameters, the assay acceptance criteria (Z-prime, signal window), and honest flagging of compounds that misbehaved, not just a tidy IC50 table. Confirm turnaround on the panel and not only the bench time, since a fast assay with a slow report still stalls your decision. Use the checklist below to compare two or three vendors against the same written scope.

• Quality and GxP status: most in vitro pharmacology is non-GLP and decision-grade, so confirm whether you actually need GLP for a given assay (you usually do not) and avoid paying GLP premiums for exploratory work. Ask about assay qualification, SOPs, and data-integrity practices.
• Assay and target-class fit: confirm the specific assay (your exact target, receptor subtype, or ion channel) is already validated and running in-house, ideally with reference compounds and historical control data, not built fresh for your project.
• Modality fit: match the menu to small molecule, antibody, peptide, oligonucleotide, ADC, or cell and gene therapy, since binding (SPR/BLI), functional potency, and selectivity formats differ completely across these.
• Capacity and lead time: ask about the current queue and realistic report turnaround, not just bench time. A great lab booked solid for months can be slower than a good lab with an open slot.
• Sensitivity and range: confirm the assay's dynamic range and detection limit cover the potency you expect, so a sub-nanomolar compound is not flattened against an assay floor.
• Data quality and reporting: insist on raw dose-response curves, fit parameters, acceptance criteria (Z-prime, signal-to-background), and clear flagging of failed or anomalous wells.
• Region and regulatory track record: if any data will feed an IND, confirm the vendor can run the relevant assay to GLP when needed and has supported submissions in your target region.
• IP and confidentiality: settle who owns the data and any assay-derived findings, and confirm a CDA is in place before you disclose a sensitive target or compound structure.